Cytokine modulation of atopic dermatitis filaggrin skin expression
- PMID: 17512043
- PMCID: PMC2669594
- DOI: 10.1016/j.jaci.2007.04.031
Cytokine modulation of atopic dermatitis filaggrin skin expression
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by a defective skin barrier function. Recent studies have reported mutations of the skin barrier gene encoding filaggrin in a subset of patients with AD.
Objective: We investigated whether reduced filaggrin expression was found in patients with AD who were not carriers of known filaggrin mutations and whether filaggrin expression was modulated by the atopic inflammatory response.
Methods: Filaggrin expression was measured in skin biopsies and cultured keratinocytes using real-time RT-PCR and immunohistochemistry. Filaggrin loss-of-function mutations were screened in a total of 69 subjects.
Results: Compared with normal skin, filaggrin expression was significantly reduced (P < .05) in acute AD skin, with further reduction seen in acute lesions from 3 European American subjects with AD who were heterozygous for the 2282del4 mutation. This was confirmed by using immunohistochemistry. AD skin is characterized by the overexpression of IL-4 and IL-13. Keratinocytes differentiated in the presence of IL-4 and IL-13 exhibited significantly reduced filaggrin gene expression (0.04 +/- 0.01 ng filaggrin/ng glyceraldehyde 3-phosphate dehydrogenase; P < .05) compared with media alone (0.16 +/- 0.03).
Conclusion: Patients with AD have an acquired defect in filaggrin expression that can be modulated by the atopic inflammatory response.
Clinical implications: The atopic immune response contributes to the skin barrier defect in AD; therefore, neutralization of IL-4 and IL-13 could improve skin barrier integrity.
Conflict of interest statement
We have no conflicts of interest to declare.
Figures






Republished in
-
Cytokine modulation of atopic dermatitis filaggrin skin expression.J Allergy Clin Immunol. 2009 Sep;124(3 Suppl 2):R7-R12. doi: 10.1016/j.jaci.2009.07.012. J Allergy Clin Immunol. 2009. PMID: 19720210
Similar articles
-
Cytokine modulation of atopic dermatitis filaggrin skin expression.J Allergy Clin Immunol. 2009 Sep;124(3 Suppl 2):R7-R12. doi: 10.1016/j.jaci.2009.07.012. J Allergy Clin Immunol. 2009. PMID: 19720210
-
Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin.J Allergy Clin Immunol. 2013 Apr;131(4):1094-102. doi: 10.1016/j.jaci.2012.12.1566. Epub 2013 Feb 10. J Allergy Clin Immunol. 2013. PMID: 23403047
-
Topical Glucose Induces Claudin-1 and Filaggrin Expression in a Mouse Model of Atopic Dermatitis and in Keratinocyte Culture, Exerting Anti-inflammatory Effects by Repairing Skin Barrier Function.Acta Derm Venereol. 2018 Jan 12;98(1):19-25. doi: 10.2340/00015555-2807. Acta Derm Venereol. 2018. PMID: 28967978
-
Revisiting the Roles of Filaggrin in Atopic Dermatitis.Int J Mol Sci. 2022 May 10;23(10):5318. doi: 10.3390/ijms23105318. Int J Mol Sci. 2022. PMID: 35628125 Free PMC article. Review.
-
Loss-of-function mutations within the filaggrin gene and atopic dermatitis.Curr Probl Dermatol. 2011;41:35-46. doi: 10.1159/000323291. Epub 2011 May 12. Curr Probl Dermatol. 2011. PMID: 21576945 Review.
Cited by
-
Phenotypes, endotypes and genotypes of atopic dermatitis and allergy in populations of African ancestry on the continent and diaspora.Front Allergy. 2024 Jan 24;4:1203304. doi: 10.3389/falgy.2023.1203304. eCollection 2023. Front Allergy. 2024. PMID: 38327736 Free PMC article. Review.
-
Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort.Allergy. 2021 Jan;76(1):302-313. doi: 10.1111/all.14489. Epub 2020 Aug 9. Allergy. 2021. PMID: 32640045 Free PMC article.
-
Epidermal barrier in atopic dermatitis.Allergy Asthma Immunol Res. 2012 Jan;4(1):12-6. doi: 10.4168/aair.2012.4.1.12. Epub 2011 Sep 21. Allergy Asthma Immunol Res. 2012. PMID: 22211165 Free PMC article.
-
Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections.J Allergy Clin Immunol. 2022 Sep;150(3):640-648. doi: 10.1016/j.jaci.2022.02.027. Epub 2022 Mar 15. J Allergy Clin Immunol. 2022. PMID: 35304160 Free PMC article.
-
Keratinocytes: An Enigmatic Factor in Atopic Dermatitis.Cells. 2022 May 19;11(10):1683. doi: 10.3390/cells11101683. Cells. 2022. PMID: 35626720 Free PMC article. Review.
References
-
- Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151–60. - PubMed
-
- Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol. 2006;118:178–89. - PubMed
-
- Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol. 2001;108:929–37. - PubMed
-
- Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet. 2004;13(Spec No 1):R43–55. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 AI050024/AI/NIAID NIH HHS/United States
- R01 AR041256/AR/NIAMS NIH HHS/United States
- AR41256/AR/NIAMS NIH HHS/United States
- U01 AI147462/AI/NIAID NIH HHS/United States
- M01 RR00051/RR/NCRR NIH HHS/United States
- R21 AR051634-01/AR/NIAMS NIH HHS/United States
- HHSN266200400029C/AI/NIAID NIH HHS/United States
- N01 AI040030/AI/NIAID NIH HHS/United States
- R21 AR051634/AR/NIAMS NIH HHS/United States
- N01 AI040029/AI/NIAID NIH HHS/United States
- M01 RR000051/RR/NCRR NIH HHS/United States
- R01 AI045839/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials